11.beta.-phenyl-4,9,15-estratrienes, their manufacture and
pharmaceutical preparations containing same
    3.
    发明授权
    11.beta.-phenyl-4,9,15-estratrienes, their manufacture and pharmaceutical preparations containing same 失效
    11(BETA)-PHENYL-4,9,15-ESTRATRIENES,其制造和含有其的药物制剂

    公开(公告)号:US5132299A

    公开(公告)日:1992-07-21

    申请号:US458668

    申请日:1990-01-16

    摘要: New 11.beta. phenyl-4,9,15-estratrienes of formula I ##STR1## are described, where X implies an oxygen atom or a hydroxyimino grouping N.about.OH,R.sup.1 stands for a hydrogen atom or a methyl group,R.sup.2 implies a hydrogen atom, an alkyl radical or an acyl radical with in each case 1 to 10 carbon atoms,R.sup.3 stands for a hydrogen atom, a cyanomethyl group, --(CH.sub.2).sub.n CH.sub.2 Z where n implies the numbers 0, 1, 2, 3, 4 or 5, Z=--H or --OR.sup.5 with R.sup.5 having the significance of a hydrogen atom or an alkyl or acyl group with in each case 1 to 10 carbon atoms, or for --(CH.sub.2).sub.m --C.tbd.C--Y where m=0-2 and Y implies a hydrogen, chlorine, fluorine, iodine or bromine atom, an alkyl, hydroxyalkyl, alkoxyalkyl or acyloxyalkyl group with in each case 1 to 10 carbon atoms,R.sup.4 represents a straight-chain or branched-chain, saturated or unsaturated hydrocarbon radical with up to 8 carbon atoms which contains the grouping ##STR2## with X having the above significance. The compounds have antigestagenic and antiglucocorticoid activity.

    摘要翻译: PCT No.PCT / DE88 / 00447 Sec。 371日期1990年1月16日 102(e)日期1990年1月16日PCT提交1988年7月15日PCT公布。 出版物WO89 / 00578 日本1月26日,1989年。新的11β型苯基-4,9,15-雌三醇,其中X表示氧原子或羟基亚氨基,N代表OH,R1代表氢 原子或甲基,R2表示氢原子,烷基或酰基,在每种情况下为1-10个碳原子,R3表示氢原子,氰基甲基, - (CH2)nCH2Z其中n表示数字 0,1,2,3,4或5,Z = -H或-OR 5,其中R 5具有氢原子或烷基或酰基的含义,在每种情况下为1-10个碳原子,或 - (CH 2) mC 3BOND CY,其中m = 0-2,Y表示氢,氯,氟,碘或溴原子,烷基,羟基烷基,烷氧基烷基或酰氧基烷基,在每种情况下为1-10个碳原子,R4表示直链或 含有至多8个碳原子的支链,饱和或不饱和烃基,其含有具有上述意义的X的分组。 这些化合物具有抗前列腺素和抗糖皮质激素活性。

    11.beta.-phenyl-14.beta.H steroids
    4.
    发明授权
    11.beta.-phenyl-14.beta.H steroids 失效
    11(BETA)-PHENYL-14(BETA)H STEROIDS

    公开(公告)号:US5244886A

    公开(公告)日:1993-09-14

    申请号:US663819

    申请日:1991-03-20

    摘要: New 11.beta.-phenyl-14.beta.H-steroids of general formula (I), where Z is an oxygen atom or the hydroxyimino-grouping N.about.OH, and M and N are either jointly a second compound or L is a hydrogen atom and M is an .alpha.-permanent hydroxy group and either A and B together are a second compound and D is a hydrogen atom, where R.sup.1 is a five or six-part heteroalkyl residue or a cycloalkyl, cycloalkenyl or aryl residue or A is a hydrogen atom and B and D together are a methylene bridge, where R.sup.1 besides the aforementioned residues may be a possibly substituted hydrocarbon residue with up to 10 C atoms, a possibly substituted amino group, a hydroxy or C.sub.1-8 alkoxy, mercapto or thioalkyl group, R.sup.2 is a methyl or ethyl residue, and R.sup.3 /R.sup.4 represents the usual combination of substituents on the C17 atom in steroid chemistry, having antigestagenic and other properties.

    摘要翻译: PCT No.PCT / EP89 / 01090 371日期1991年3月20日 102(e)1991年3月20日PCT PCT 1989年9月20日PCT公布。 出版物WO90 / 03385 日本1994年4月5日。通式(I)的新的11β-苯基-14βH-类固醇,其中Z是氧原子或羟基亚氨基基团N差异OH,M和N或者是共同的第二化合物 或L是氢原子,M是α-永久性羟基,A和B一起是第二化合物,D是氢原子,其中R 1是五或六部分杂烷基残基或环烷基,环烯基或芳基 残基或A是氢原子,B和D一起是亚甲基桥,其中除了上述残基之外,R 1可以是具有至多10个C原子的可能取代的烃残基,可能被取代的氨基,羟基或C 1-8烷氧基 ,巯基或硫代烷基,R2是甲基或乙基残基,R3 / R4代表类固醇化学中C17原子上取代基的通常组合,具有抗原原性和其他性质。

    D-homo-(16-ene)-11.beta.-aryl-4-estrenes, process for their production
as well as their use as pharmaceutical agents
    8.
    发明授权
    D-homo-(16-ene)-11.beta.-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents 失效
    D-均聚(16-烯)-11β-芳基-4-雌酮,其制备方法以及作为药剂的用途

    公开(公告)号:US5519027A

    公开(公告)日:1996-05-21

    申请号:US78326

    申请日:1994-02-25

    CPC分类号: C07J63/008

    摘要: New D-homo-(16-ene)-11.beta.-aryl-4-estrenes of general formula I ##STR1## as well as their pharmaceutically compatible addition salts with acids are described in whichX stands for an oxygen atom, the hydroxyimino grouping >N.about.OH or two hydrogen atoms,R.sup.1 stands for a hydrogen atom or a methyl group,R.sup.2 stands for an hydroxy group, a C.sub.1 -C.sub.10 alkoxy or C.sub.1 -C.sub.10 acyloxy group,R.sup.11 stands for a fluorine, chlorine or bromine atom, and then R.sup.12 and R.sup.13 together mean an additional bond orR.sup.11 stands for a straight-chain or branched-chain C.sub.1 -C.sub.4 -alkyl radical or a hydrogen atom, and then R.sup.12 and R.sup.13 each mean a hydrogen atom or together mean an additional bond,and R.sup.3 and R.sup.4 have the usual meanings indicated in the description for competitive progesterone antagonists.The invention further relates to a process for the production of new compounds, pharmaceutical preparations containing these compounds, their use for the production of pharmaceutical agents as well as the new intermediate products necessary for the process.The new compounds have a strong affinity to the gestagen receptor and show strong antigestagen as well as antiglucocorticoid, antimineral corticoid and antiandrogenic properties.

    摘要翻译: PCT No.PCT / EP91 / 02495 371日期1994年2月25日 102(e)1994年2月25日PCT PCT 1991年12月21日PCT公布。 出版物WO92 / 11279 日期:1992年7月9日。通式I(I)的新型D-均 - (16-烯)-11β-芳基-4-雌酮及其与酸的药学上相容的加成盐描述于其中 X表示氧原子,羟基亚氨基> N不同OH或两个氢原子,R1表示氢原子或甲基,R2表示羟基,C1-C10烷氧基或C1-C10酰氧基,R11 代表氟,氯或溴原子,然后R 12和R 13一起表示另外的键或R 11表示直链或支链的C 1 -C 4烷基或氢原子,则R 12和R 13各自表示 氢原子或一起表示另外的键,并且R3和R4具有在竞争性孕酮拮抗剂的描述中指出的通常含义。 本发明还涉及生产新化合物的方法,含有这些化合物的药物制剂,其用于生产药物的用途以及该方法所需的新的中间产物。 新化合物对孕激素受体具有强烈的亲和力,并显示出强的抗老化,以及抗糖皮质激素,抗癫痫皮质激素和抗雄激素的特性。